SCHEMBL3490635

SCHEMBL3490635

Cc1c(C(=O)O)sc2nc(Cc3ccccc3Cl)[nH]c(=O)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.58
KMT2A Q03164 9/20 0.58
MEN1 O00255 6/20 0.58
KDM4E B2RXH2 3/20 0.58
MAPT P10636 6/20 0.57
POLB P06746 7/20 0.53
TDP1 Q9NUW8 6/20 0.53
MCL1 Q07820 2/20 0.53
HPGD P15428 1/20 0.53
APEX1 P27695 1/20 0.53
RECQL P46063 1/20 0.53
L3MBTL1 Q9Y468 5/20 0.53
PLEC Q15149 1/20 0.52
LMNA P02545 2/20 0.52
USP2 O75604 1/20 0.52
THRB P10828 1/20 0.52
APOBEC3A P31941 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
HTT P42858 1/20 0.51
PIP4K2A P48426 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493536 0.91 MAPT (0.55) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3493377 0.89 MAPT (0.53) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3494404 0.89 MAPT (0.61) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3490758 0.88 ALDH1A1 (0.59) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL4506234 0.87 KMT2A (0.76) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3493056 0.87 MAPT (0.55) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3493776 0.87 ALDH1A1 (0.58) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL13341339 0.86 ALDH1A1 (0.75) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3493917 0.86 KMT2A (0.57) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3491611 0.85 KMT2A (0.56) ALDH1A1KMT2AMEN1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD ALDH1A1 762/4885KMT2A 2820/4885MEN1 3598/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 ALDH1A1 748/4885KMT2A 3654/4885MEN1 4467/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 ALDH1A1 2303/4885KMT2A 2650/4885MEN1 2509/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 ALDH1A1 2303/4885KMT2A 2650/4885MEN1 2509/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 ALDH1A1 748/4885KMT2A 3654/4885MEN1 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.